Ann: Positive preclinical data for deoxymabs in vasculitis, page-48

Dr James Campbell

CEO, Patrys Ltd

Dr James Campbell is the CEO of Patrys Limited, an ASX-listed biotech company developing novel antibody therapeutics for cancer. As a senior biotechnology executive, Dr Campbell’s successful career in biotech includes bench research, academic technology transfer, establishment of early-stage start-ups, leading private and public companies, and being involved in hundred million-dollar deals. With more than 25 years’ experience in research, research management, consulting and venture capital in Australia and internationally, Dr Campbell has a unique set of skills that enable him to identify and monetise future trends in the biotech and pharmaceutical industries.

Dr Campbell sits on the Board of Directors of ASX-listed biotech company Prescient Therapeutics, and has previously served on the Advisory Board for the Centre for Innovation in Mental and Physical Health and Clinical Treatment at Deakin University, the IP and Commercialisation Committee of the Cooperative Research Centre for Mental Health and several government advisory panels.

Holding a PhD in plant biochemistry, Dr Campbell completed a MBA at the Melbourne Business School, and is a Graduate of the Australian Institute of Company Directors.

Seems well qualified on paper.

The production run failure is not a matter by which he can or should be judged as drug production runs are notoriously unreliable. ‘In 2019 the Federal Drug Shortages Task Force reported that 62% of drugs that went into shortage between 2013 and 2017 were associated with manufacturing or product quality problems, such as substandard manufacturing processes or quality defects in the finished products.’ These were drugs already on the market and successfully produced in the past without problems.

The moral of the story problems occur even when drugs have been successfully produced.

ncbi.non.nih.gov/once/articles/PMC9589742/

My opinion only DYOR

Fact Finder